Humacyte (HUMA) Twitter Mentions Statistics 2025

203 37.7%

1W 49.5% 1M 80% 3M 82.7%

Est. daily mentions on Twitter.

Similar companies

Company		Twitter Mentions
	Amgen AMGN	51 15%
	Gilead Sciences GILD	22 78.6%
	Inovio Pharmaceuticals INO	19 9.5%
	Anavex Life Sciences AVXL	26 188.9%
	BridgeBio Pharma BBIO	15 53.1%

Month over Month

Est. daily mentions on Twitter.

Aug 2025	1,288	23.3%
Jul 2025	1,044	14.7%
Jun 2025	910	6.3%
May 2025	856

How often is HUMA mentioned on X?

The cashtag $HUMA was mentioned an estimated 203 times in X posts yesterday.

Analyzing Twitter Mentions, how is Humacyte performing compared to its industry peers?

Humacyte underperforms its industry peers when it comes to Twitter Mentions, ranking in the 22nd percentile.

Why is it important to track Twitter mentions for Humacyte?

By monitoring Twitter mentions for Humacyte, investors gain real-time insights into public sentiment towards the company, its products, and its industry. Positive mentions may indicate growing interest, customer satisfaction, or emerging trends, while negative mentions can alert investors to potential issues, controversies, or market challenges. By tracking these mentions over time, investors can identify patterns, spot emerging trends, and make informed decisions based on the evolving sentiment and public perception of Humacyte, ultimately improving their investment strategies.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.